Patents by Inventor Andreas Striebinger

Andreas Striebinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID beta (Abeta) AMINO ACID SEQUENCES AND USES THEREOF
    Publication number: 20240075114
    Abstract: The invention relates to immunogenic products based on mutein amyloid ? (A?) amino acid sequences, in particular to oligomers of A? muteins, and to the use of said products in diagnosis, treatment and prevention of conditions such as amyloidoses, and for identifying agents capable of binding to said products.
    Type: Application
    Filed: October 27, 2022
    Publication date: March 7, 2024
    Inventors: Stefan Barghorn, Simone Giaisi, Heinz Hillen, Andreas Striebinger
  • MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEIN AND USES THEREOF
    Publication number: 20220017607
    Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment, and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
    Type: Application
    Filed: February 22, 2021
    Publication date: January 20, 2022
    Applicants: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO KG
    Inventors: Heinz HILLEN, Stefan BARGHORN, Boris LABKOVSKY, Ulrich EBERT, Andreas STRIEBINGER, Patrick KELLER
  • RGMa Fragment Based Diagnostic Assay
    Publication number: 20220018855
    Abstract: Provided are diagnostic assays and method s of using the diagnostic assays for detecting and quantifying RGMa fragments in a sample. The methods may be used detection of the RGMa fragments to monitoring drug treatment and effectiveness of drug treatment in neurodegenerative diseases.
    Type: Application
    Filed: March 2, 2021
    Publication date: January 20, 2022
    Inventors: Stefan Barghorn, Bernhard Klaus Mueller, Martin Schmidt, Andreas Striebinger
  • RGMa Fragment Based Diagnostic Assay
    Publication number: 20200241012
    Abstract: Provided are diagnostic assays and method s of using the diagnostic assays for detecting and quantifying RGMa fragments in a sample. The methods may be used detection of the RGMa fragments to monitoring drug treatment and effectiveness of drug treatment in neurodegenerative diseases.
    Type: Application
    Filed: September 4, 2019
    Publication date: July 30, 2020
    Inventors: Stefan Barghorn, Bernhard Klaus Mueller, Martin Schmidt, Andreas Striebinger
  • Amyloid ?(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
    Patent number: 10464976
    Abstract: The invention relates to neuromodulatory oligomers of the amyloid-?(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers as diagnostic and therapeutics agents, for the generation of oligomer-specific antibodies and for the discovery of substances which can interact with the oligomers and in the formation thereof. Corresponding methods for the production of the antibodies and for discovery of the substances are also disclosed as are the antibodies themselves and the use of the antibodies or substances as diagnostic and therapeutic agents. The invention further relates to derivatives of the oligomers and oligomers based on abbreviated forms of the amyloid-?(1-42) proteins, the production and use thereof.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: November 5, 2019
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Heinz Hillen, Andreas Striebinger, Carsten Krantz, Achim Moeller, Reinhold Mueller
  • Monoclonal antibodies against amyloid beta protein and uses thereof
    Patent number: 10323084
    Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: June 18, 2019
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Heinz Hillen, Stefan Barghorn, Boris Labkovsky, Ulrich Ebert, Andreas Striebinger, Patrick Keller
  • Amyloid-beta binding proteins
    Patent number: 10047121
    Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to ??(20-42) globulomer or any ?? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: August 14, 2018
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giaisi, Ulrich Ebert, Chung-Ming Hsieh
  • AMYLOID-BETA BINDING PROTEINS
    Publication number: 20180094049
    Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any A? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
    Type: Application
    Filed: October 17, 2017
    Publication date: April 5, 2018
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giaisi, Ulrich Ebert, Lorenzo Benatuil
  • MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEIN AND USES THEREOF
    Publication number: 20180066044
    Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
    Type: Application
    Filed: July 27, 2017
    Publication date: March 8, 2018
    Inventors: Heinz HILLEN, Stefan BARGHORN, Boris LABKOVSKY, Ulrich EBERT, Andreas STRIEBINGER, Patrick KELLER
  • Amyloid-beta binding proteins
    Patent number: 9822171
    Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any A? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: November 21, 2017
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giaisi, Ulrich Ebert, Lorenzo Benatuil
  • MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEIN AND USES THEREOF
    Publication number: 20160159891
    Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
    Type: Application
    Filed: February 17, 2016
    Publication date: June 9, 2016
    Inventors: Heinz Hillen, Stefan Barghorn, Boris Labkovsky, Ulrich Ebert, Andreas Striebinger, Patrick Keller
  • AMYLOID BETA(1-42) OLIGOMERS, DERIVATIVES THEREOF AND ANTIBODIES THERETO, METHODS OF PREPARATION THEREOF AND USE THEREOF
    Publication number: 20160090406
    Abstract: The invention relates to neuromodulatory oligomers of the amyloid-?(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers as diagnostic and therapeutics agents, for the generation of oligomer-specific antibodies and for the discovery of substances which can interact with the oligomers and in the formation thereof. Corresponding methods for the production of the antibodies and for discovery of the substances are also disclosed as are the antibodies themselves and the use of the antibodies or substances as diagnostic and therapeutic agents. The invention further relates to derivatives of the oligomers and oligomers based on abbreviated forms of the amyloid-?(1-42) proteins, the production and use thereof.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 31, 2016
    Inventors: Heinz Hillen, Andreas Striebinger, Carsten Krantz, Achim Moeller, Reinhold Mueller
  • RGMa Fragment Based Diagnostic Assay
    Publication number: 20160069907
    Abstract: Provided are diagnostic assays and method s of using the diagnostic assays for detecting and quantifying RGMa fragments in a sample. The methods may be used detection of the RGMa fragments to monitoring drug treatment and effectiveness of drug treatment in neurodegenerative diseases.
    Type: Application
    Filed: September 10, 2015
    Publication date: March 10, 2016
    Inventors: Stefan Barghorn, Bernhard Klaus Mueller, Martin Schmidt, Andreas Striebinger
  • IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID beta (Abeta) AMINO ACID SEQUENCES AND USES THEREOF
    Publication number: 20160000891
    Abstract: The invention relates to immunogenic products based on mutein amyloid ? (A?) amino acid sequences, in particular to oligomers of A? muteins, and to the use of said products in diagnosis, treatment and prevention of conditions such as amyloidoses, and for identifying agents capable of binding to said products.
    Type: Application
    Filed: July 6, 2015
    Publication date: January 7, 2016
    Inventors: Stefan Barghorn, Simone Giaisi, Heinz Hillen, Andreas Striebinger
  • AMYLOID-BETA BINDING PROTEINS
    Publication number: 20150368299
    Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any ? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
    Type: Application
    Filed: June 22, 2015
    Publication date: December 24, 2015
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giaisi, Ulrich Ebert, Chung-Ming Hsieh
  • Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
    Patent number: 9176150
    Abstract: The invention relates to neuromodulatory oligomers of the amyloid-?(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers as diagnostic and therapeutics agents, for the generation of oligomer-specific antibodies and for the discovery of substances which can interact with the oligomers and in the formation thereof. Corresponding methods for the production of the antibodies and for discovery of the substances are also disclosed as are the antibodies themselves and the use of the antibodies or substances as diagnostic and therapeutic agents. The invention further relates to derivatives of the oligomers and oligomers based on abbreviated forms of the amyloid-?(1-42) proteins, the production and use thereof.
    Type: Grant
    Filed: August 1, 2011
    Date of Patent: November 3, 2015
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Heinz Hillen, Andreas Striebinger, Carsten Krantz, Achim Moeller, Reinhold Mueller
  • AMYLOID-BETA BINDING PROTEINS
    Publication number: 20150218261
    Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any A? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
    Type: Application
    Filed: February 10, 2015
    Publication date: August 6, 2015
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giaisi, Ulrich Ebert, Lorenzo Benatuil
  • Amyloid-beta binding proteins
    Patent number: 9062101
    Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any A? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: June 23, 2015
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giaisi, Ulrich Ebert, Chung-Ming Hsieh
  • Amyloid-beta binding proteins
    Patent number: 8987419
    Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any A? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: March 24, 2015
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giaisi, Ulrich Ebert, Lorenzo Benatuil
  • MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEIN AND USES THEREOF
    Publication number: 20150071915
    Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
    Type: Application
    Filed: June 12, 2014
    Publication date: March 12, 2015
    Inventors: Heinz Hillen, Stefan Barghorn, Boris Labkovsky, Ulrich Ebert, Andreas Striebinger, Patrick Keller